SolarWindow Technologies, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SolarWindow Technologies, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Aug 31, 2024 | $0 | Nov 20, 2024 |
| FY2024 | Aug 31, 2023 | $0 | Nov 20, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | ($2.26M) | Nov 13, 2025 |
| FY2025 | Aug 31, 2024 | ($3.46M) | Nov 13, 2025 |
| FY2024 | Aug 31, 2023 | ($2.40M) | Nov 20, 2024 |
| FY2023 | Aug 31, 2022 | ($4.95M) | Nov 21, 2023 |
| FY2022 | Aug 31, 2021 | ($7.91M) | Aug 30, 2023 |
| FY2021 | Aug 31, 2020 | ($7.35M) | Nov 4, 2021 |
| FY2019 | Aug 31, 2019 | ($3.39M) | Nov 18, 2019 |
| FY2019 | May 31, 2019 | ($987.3K) | Nov 18, 2019 |
| FY2019 | Feb 28, 2019 | ($826.8K) | Nov 18, 2019 |
| FY2019 | Nov 30, 2018 | ($1.69M) | Nov 18, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | ($2.36M) | Nov 13, 2025 |
| FY2025 | Aug 31, 2024 | ($2.61M) | Nov 13, 2025 |
| FY2024 | Aug 31, 2023 | ($2.31M) | Nov 20, 2024 |
| FY2023 | Aug 31, 2022 | ($3.75M) | Nov 21, 2023 |
| FY2022 | Aug 31, 2021 | ($7.94M) | Aug 30, 2023 |
| FY2021 | Aug 31, 2020 | ($7.60M) | Nov 4, 2021 |
| FY2020 | Aug 31, 2019 | ($6.41M) | Nov 10, 2020 |
| FY2019 | Aug 31, 2018 | ($5.55M) | Nov 18, 2019 |
| FY2018 | Aug 31, 2017 | ($3.73M) | Nov 29, 2018 |
| FY2018 | Aug 31, 2016 | ($3.14M) | Nov 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $621.9K | Nov 13, 2025 |
| FY2025 | Aug 31, 2024 | $594.0K | Nov 13, 2025 |
| FY2024 | Aug 31, 2023 | $764.8K | Nov 20, 2024 |
| FY2023 | Aug 31, 2022 | $902.0K | Nov 21, 2023 |
| FY2022 | Aug 31, 2021 | $1.66M | Aug 30, 2023 |
| FY2021 | Aug 31, 2020 | $2.28M | Nov 4, 2021 |
| FY2020 | Aug 31, 2019 | $1.98M | Nov 10, 2020 |
| FY2019 | Aug 31, 2018 | $1.93M | Nov 18, 2019 |
| FY2018 | Aug 31, 2017 | $950.5K | Nov 29, 2018 |
| FY2018 | Aug 31, 2016 | $822.9K | Nov 29, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $1.73M | Nov 13, 2025 |
| FY2025 | Aug 31, 2024 | $2.01M | Nov 13, 2025 |
| FY2025 | Feb 5, 2024 | $26.8K | Nov 13, 2025 |
| FY2024 | Aug 31, 2023 | $1.55M | Nov 20, 2024 |
| FY2023 | Aug 31, 2022 | $2.85M | Nov 21, 2023 |
| FY2022 | Aug 31, 2021 | $6.28M | Aug 30, 2023 |
| FY2021 | Aug 31, 2020 | $5.32M | Nov 4, 2021 |
| FY2020 | Aug 31, 2019 | $4.43M | Nov 10, 2020 |
| FY2019 | Aug 31, 2018 | $3.62M | Nov 18, 2019 |
| FY2018 | Aug 31, 2017 | $2.78M | Nov 29, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | ($1.50M) | Nov 13, 2025 |
| FY2025 | Aug 31, 2024 | ($1.74M) | Nov 13, 2025 |
| FY2024 | Aug 31, 2023 | ($2.08M) | Nov 20, 2024 |
| FY2023 | Aug 31, 2022 | ($3.64M) | Nov 21, 2023 |
| FY2022 | Aug 31, 2021 | ($2.66M) | Aug 30, 2023 |
| FY2021 | Aug 31, 2020 | ($2.45M) | Nov 4, 2021 |
| FY2020 | Aug 31, 2019 | ($2.55M) | Nov 10, 2020 |
| FY2019 | Aug 31, 2018 | ($2.92M) | Nov 18, 2019 |
| FY2018 | Aug 31, 2017 | ($2.77M) | Nov 29, 2018 |
| FY2018 | Aug 31, 2016 | ($2.63M) | Nov 29, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $37.7K | Nov 13, 2025 |
| FY2025 | Aug 31, 2024 | $1.9K | Nov 13, 2025 |
| FY2024 | Aug 31, 2023 | $0 | Nov 20, 2024 |
| FY2023 | Aug 31, 2022 | $357.0K | Nov 21, 2023 |
| FY2022 | Aug 31, 2021 | $76.3K | Aug 30, 2023 |
| FY2020 | Aug 31, 2020 | $5.0K | Nov 10, 2020 |
| FY2020 | Aug 31, 2019 | $1.35M | Nov 10, 2020 |
| FY2019 | Aug 31, 2018 | $2.6K | Nov 18, 2019 |
| FY2018 | Aug 31, 2017 | $45.5K | Nov 29, 2018 |
| FY2018 | Aug 31, 2016 | $2.3K | Nov 29, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $6.65M | Nov 13, 2025 |
| FY2025 | Aug 31, 2024 | $5.00M | Nov 13, 2025 |
| FY2024 | Aug 31, 2023 | $7.62M | Nov 20, 2024 |
| FY2023 | Aug 31, 2022 | $9.69M | Nov 21, 2023 |
| FY2022 | Aug 31, 2021 | $13.73M | Aug 30, 2023 |
| FY2021 | Aug 31, 2020 | $16.18M | Nov 4, 2021 |
| FY2020 | Aug 31, 2019 | $18.67M | Nov 10, 2020 |
| FY2019 | Aug 31, 2018 | $929.2K | Nov 18, 2019 |
| FY2018 | Aug 31, 2017 | $831.7K | Nov 29, 2018 |
| FY2017 | Aug 31, 2016 | $2.90M | Nov 22, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $194.2K | Nov 13, 2025 |
| FY2025 | Aug 31, 2024 | $321.5K | Nov 13, 2025 |
| FY2024 | Aug 31, 2023 | $287.2K | Nov 20, 2024 |
| FY2023 | Aug 31, 2022 | $118.4K | Nov 21, 2023 |
| FY2022 | Aug 31, 2021 | $170.2K | Aug 30, 2023 |
| FY2021 | Aug 31, 2020 | $209.2K | Nov 4, 2021 |
| FY2020 | Aug 31, 2019 | $221.2K | Nov 10, 2020 |
| FY2019 | Aug 31, 2018 | $4.55M | Nov 18, 2019 |
| FY2018 | Aug 31, 2017 | $4.46M | Nov 29, 2018 |
| FY2017 | Aug 31, 2016 | $2.81M | Nov 22, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $6.45M | Nov 13, 2025 |
| FY2025 | Aug 31, 2024 | $4.68M | Nov 13, 2025 |
| FY2025 | Aug 31, 2023 | $7.33M | Nov 13, 2025 |
| FY2024 | Aug 31, 2022 | $9.57M | Nov 20, 2024 |
| FY2023 | Aug 31, 2021 | $13.56M | Nov 21, 2023 |
| FY2022 | Aug 31, 2020 | ($15.97M) | Aug 30, 2023 |
| FY2021 | Aug 31, 2019 | $18.45M | Nov 4, 2021 |
| FY2020 | Aug 31, 2018 | ($3.62M) | Nov 10, 2020 |
| FY2019 | Aug 31, 2017 | ($3.63M) | Nov 18, 2019 |
| FY2018 | Aug 31, 2016 | $81.9K | Nov 29, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | ($81.09M) | Nov 13, 2025 |
| FY2025 | Aug 31, 2024 | ($78.83M) | Nov 13, 2025 |
| FY2024 | Aug 31, 2023 | ($75.38M) | Nov 20, 2024 |
| FY2023 | Aug 31, 2022 | ($72.98M) | Nov 21, 2023 |
| FY2022 | Aug 31, 2021 | ($68.03M) | Aug 30, 2023 |
| FY2021 | Aug 31, 2020 | ($60.13M) | Nov 4, 2021 |
| FY2020 | Aug 31, 2019 | ($52.77M) | Nov 10, 2020 |
| FY2019 | Aug 31, 2018 | ($45.88M) | Nov 18, 2019 |
| FY2018 | Aug 31, 2017 | ($39.03M) | Nov 29, 2018 |
| FY2017 | Aug 31, 2016 | ($33.68M) | Nov 22, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $6.56M | Nov 13, 2025 |
| FY2025 | Aug 31, 2024 | $1.25M | Nov 13, 2025 |
| FY2023 | Aug 31, 2023 | $492.6K | Nov 21, 2023 |
| FY2023 | Aug 31, 2022 | $8.08M | Nov 21, 2023 |
| FY2022 | Aug 31, 2021 | $7.13M | Aug 30, 2023 |
| FY2021 | Aug 31, 2020 | $14.15M | Nov 4, 2021 |
| FY2021 | Aug 31, 2019 | $16.60M | Nov 4, 2021 |
| FY2020 | Aug 31, 2018 | $696.8K | Nov 10, 2020 |
| FY2019 | Aug 31, 2017 | $670.9K | Nov 18, 2019 |
| FY2018 | Aug 31, 2016 | $2.51M | Nov 29, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Aug 31, 2018 | $600.0K | Nov 18, 2019 |
| FY2018 | Aug 31, 2017 | $600.0K | Nov 29, 2018 |
| FY2016 | Aug 31, 2016 | $525.3K | Nov 21, 2016 |
| FY2016 | Aug 31, 2015 | $593.5K | Nov 21, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 0 | Nov 13, 2025 |
| FY2025 | Aug 31, 2024 | 0 | Nov 13, 2025 |
| FY2024 | Aug 31, 2023 | 0 | Nov 20, 2024 |
| FY2023 | Aug 31, 2022 | 0 | Nov 21, 2023 |
| FY2022 | Aug 31, 2021 | 0 | Aug 30, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 0 | Nov 13, 2025 |
| FY2025 | Aug 31, 2024 | 0 | Nov 13, 2025 |
| FY2024 | Aug 31, 2023 | 0 | Nov 20, 2024 |
| FY2023 | Aug 31, 2022 | 0 | Nov 21, 2023 |
| FY2022 | Aug 31, 2021 | 0 | Aug 30, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 65.78M | Nov 13, 2025 |
| FY2025 | Aug 31, 2024 | 53.20M | Nov 13, 2025 |
| FY2024 | Aug 31, 2023 | 53.20M | Nov 20, 2024 |
| FY2023 | Aug 31, 2022 | 53.20M | Nov 21, 2023 |
| FY2022 | Aug 31, 2021 | 53.20M | Aug 30, 2023 |
| FY2021 | Aug 31, 2020 | 52.96M | Nov 4, 2021 |
| FY2020 | Aug 31, 2019 | 52.96M | Nov 10, 2020 |
| FY2019 | Aug 31, 2018 | 36.29M | Nov 18, 2019 |
| FY2018 | Aug 31, 2017 | 34.33M | Nov 29, 2018 |
| FY2018 | Aug 31, 2016 | 28.50M | Nov 29, 2018 |